All articles by
SolutionHealth and Acadia Healthcare Form Joint Venture to Build a Behavioral Health Hospital in Southeast New Hampshire
This project will also be supported by $15 million in state funding from the New Hampshire Department of Health and Human Services to defray capital costs for the construction of the new hospital
AstraZeneca’s Imfinzi/Imjudo combo shows positive results in liver cancer study
According to the results, a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen, reduced the risk of death by 22% compared to sorafenib at four years of follow-up
FDA approves BioMarin’s Roctavian for adults with haemophilia A
The FDA approval was based on findings from the global Phase 3 GENEr8-1 study in which the annualised bleeding rate among patients reduced 52% after receiving Roctavian
Revvity Tests Included in UK’s Updated NICE Diagnostic Guidance for Pre-Eclampsia DG-49
Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
Bionano Announces the Stratys System for OGM and VIA Software for Hematologic Malignancies
Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume users
Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Promising Results for Immunotherapy Targeting Skin Cancer
HAMBURG, Germany, June 11, 2023 /PRNewswire/ — A ground-breaking study was presented 10 June at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Study was conducted by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust has revealed promising results for a new class of immunotherapy in the fight against aggressive skin cancer. The study investigates the efficacy of a novel antibody in targeting and treating melanomas, demonstrating its ability to activate the immune response and impede melanoma growth in mice.
Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
Gibco™ OncoPro™ Tumoroid Culture Medium Kit broadens access to clinically relevant patient-derived tumor models
Bruker Announces New D6 PHASERTM Benchtop X-Ray Diffraction (XRD) Platform for Materials Analysis and Advanced Research
Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASERTM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. With its wide range of capabilities, the D6 PHASER will enable more XRD applications for new markets and user communities.
iNova to acquire Mundipharma’s consumer health product portfolio for $540m
The combined company will have a significantly wider geographic footprint with extensive coverage of Asian and Middle Eastern regions as well as an increasing presence in Europe and Canada
Japan MHLW approves GSK’s Shingrix for shingles treatment in adults
RZV is a non-live, recombinant sub-unit vaccine that combines antigen, glycoprotein E, with an adjuvant system, AS01B to generate a varicella-zoster virus (VZV)-specific immune response